We develop first-in-class biologics for underserved autoimmune conditions by targeting a new apoptosis pathway that plays a key role in the pathogenesis of these diseases.
Unlike traditional treatments, our therapeutic approach is to both inhibit stem cell apoptosis and to re-establish cell and organ function.
As we develop our science and our pipeline, we seek to establish a portfolio of strategic collaborations with key partners.
We have formed successful ongoing collaborations with leading academic centers of excellence, including the San Raffaele Hospital and University of Milan.
In addition, we have a licensing agreement with Trianni Inc for the use of their antibody discovery platform, The Trianni Mouse and we have partnered with Yumab for the development of mAbs with defined characteristics.